STERISYS is involved in the development and provision of automated handling systems and sterilization plants for the medical technology and pharmaceutical industries. The company focuses on engineering and constructing turnkey solutions for ethylene oxide sterilization.

STERISYS

Capriza provides information on tracking apps, lifestyle tips, and relationship advice, self-described.

Capriza

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Metric
Company Name	STERISYS	Capriza	Hikma Pharmaceuticals PLC
Symbol			HIK
MSH ID	EU:STERISYS	COM:CAPRIZA	COM:HIKMA
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Consumer Services	Healthcare
Industry	Medical Devices	Information Services	Drug Manufacturers - Specialty & Generic
Country	BE	US	GB
Stage
Employee Count			9.10K
Website	sterisys.eu	capriza.com	hikma.com
LinkedIn			hikma-pharmaceuticals
Founders

Metric
Market Cap			51.46M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			2.88B
Revenue (LTM)
Revenue (NTM)
Gross Profit			1.39B
EBITDA			871M
Operating Income			367M
Net Income			190M
EPS			0.86
Diluted EPS			0.85
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.50
Operating Profit Margin			0.24
EBITDA Margin			0.30
Net Profit Margin			0.09
Return on Equity			0.13
Return on Assets			0.06
Return on Capital Employed			0.21

EU:STERISYS

STERISYS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			57.06
P/B Ratio			2.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			2.00
EV Multiple			6.03

Metric
Days Sales Outstanding			287.13
Days Payables Outstanding			288.23
Days Inventory Outstanding			236.69
Operating Cycle			354.84
Cash Conversion Cycle			205.25
Asset Turnover			0.62

Metric
Operating Cash Flow			608M
Free Cash Flow			404M
Cash Flow to Debt			0.51
Operating Cash Flow/Sales			0.21
Free Cash Flow Yield			0.03

Metric
Cash & Equivalents			205M
Accounts Receivable
Inventory			891M
Goodwill			388M
Debt to Capitalization			0.36
Debt to Assets			0.28
Current Ratio			1.79
Quick Ratio			0.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.01
R&D to Revenue			0.06
SG&A to Revenue			0.20